首页> 外文期刊>Respiratory Research >Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
【24h】

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing

机译:呼吸道合胞病毒毛细支气管炎和支气管后喘息的预防和治疗

获取原文
           

摘要

Respiratory syncytial virus (RSV) is the primary cause of hospitalization for acute respiratory tract illness in general and specifically for bronchiolitis in young children. The link between RSV bronchiolitis and reactive airway disease is not completely understood, even though RSV bronchiolitis is frequently followed by recurrent episodes of wheezing. Therapy with ribavirin does not appear to significantly reduce long-term respiratory outcome of RSV lower respiratory tract infection, and corticosteroid or bronchodilator therapy may possibly improve outcomes only on a short-term basis. No vaccine against RSV is yet available. It is not known whether prophylaxis with RSV intravenous immune globulin or palivizumab can reduce postbronchiolitic wheezing.Keywords: bronchiolitis, lower respiratory tract infection, palivizumab, reactive airway disease, respiratory syncytial virus
机译:呼吸道合胞病毒(RSV)通常是急性呼吸道疾病住院的主要原因,尤其是对于年幼儿童的细支气管炎。尽管RSV细支气管炎经常伴有反复发作的喘息,但RSV细支气管炎与反应性气道疾病之间的联系尚不完全清楚。利巴韦林的治疗似乎并未显着降低RSV下呼吸道感染的长期呼吸结果,而皮质类固醇或支气管扩张剂治疗可能仅在短期基础上可改善结果。尚无针对RSV的疫苗。尚不清楚用RSV静脉注射免疫球蛋白或帕利珠单抗预防是否可以减少支气管后喘息。关键词:细支气管炎,下呼吸道感染,帕利珠单抗,反应性气道疾病,呼吸道合胞病毒

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号